| Literature DB >> 27832971 |
Francesca De Felice1, Ilaria Benevento2, Angela Musella3, Daniela Musio2, Vincenzo Tombolini4.
Abstract
Head neck cancer (HNC) is generally treated with a multimodality approach. Loco-regional-distant control is often worst, due to the advantage stage disease at diagnosis and the optimal treatment option remains an unresolved issue. Metronomic chemotherapy (MCHT) is an emerging therapeutic option in clinical oncology and it may prove useful in HNC patients.Entities:
Keywords: Head neck cancer; Low dose; Metronomic chemotherapy; Recurrence; Survival; Treatment
Mesh：
Substances：
Year: 2016 PMID： 27832971 DOI： 10.1016/j.canlet.2016.10.047
Source DB: PubMed Journal: Cancer Lett ISSN： 0304-3835 Impact factor: 8.679